Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Swiss National Bank

Key Points

• Swiss National Bank increased its holdings in Alnylam Pharmaceuticals by 0.4% during Q1, owning approximately $98 million worth of shares.
• Several research firms have boosted their price targets for Alnylam Pharmaceuticals, with Bank of America setting a new target of $359 and UBS Group raising it to $550.
• Alnylam Pharmaceuticals reported an earnings per share of $0.32 for the most recent quarter, significantly higher than analysts' estimates of ($0.54), and revenue increased by 17.3% year-over-year.

Swiss National Bank raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.4% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 364,200 shares of the biopharmaceutical company's stock after purchasing an additional 1,600 shares during the quarter. Swiss National Bank owned 0.28% of Alnylam Pharmaceuticals worth $98,341,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Investment Management Corp of Ontario lifted its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after buying an additional 40 shares in the last quarter. Brevan Howard Capital Management LP raised its stake in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 44 shares in the last quarter. Lindbrook Capital LLC raised its stake in Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock valued at $161,000 after purchasing an additional 50 shares in the last quarter. SYM FINANCIAL Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 5.3% in the 1st quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company's stock worth $274,000 after acquiring an additional 51 shares during the last quarter. Finally, Ballentine Partners LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 3.3% in the 1st quarter. Ballentine Partners LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $439,000 after acquiring an additional 52 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at $14,899,281.72. This trade represents a 39.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ALNY. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Chardan Capital raised their target price on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a "buy" rating in a research note on Friday, July 11th. Finally, Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Four investment analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $403.92.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded up $6.87 during trading hours on Thursday, hitting $439.39. 660,653 shares of the company were exchanged, compared to its average volume of 948,674. The company's 50 day moving average price is $339.44 and its 200-day moving average price is $287.99. The stock has a market capitalization of $57.60 billion, a price-to-earnings ratio of -177.77 and a beta of 0.25. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $445.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773,689 billion for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the prior year, the firm earned ($0.13) EPS. The business's revenue for the quarter was up 17.3% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.